Browsing by Author "Erglis, A"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Adherence to the “Atrial Fibrillation Better Care” (ABC) Pathway in Patients with Atrial Fibrillation and Cancer: a Report From the ESC-EHRA EURObservational Research Programme in Atrial Fibrillation (EORP-AF) General Long-Term RegistryPublication . Vitolo, M; Proietti, M; Malavasi, V; Bonini, N; Romiti, G; Imberti, J; Fauchier, L; Marin, F; Nabauer, M; Potpara, T; Dan, GA; Kalarus, Z; Maggioni, A; Lane, D; Lip, G; Boriani, G; Boriani Chair, G; Lip, G; Tavazzi, L; Maggioni, A; Dan, G; Potpara, T; Nabauer, M; Marin, F; Kalarus, Z; Fauchier, L; Goda, A; Mairesse, G; Shalganov, T; Antoniades, L; Taborsky, M; Riahi, S; Muda, P; Bolao, I; Piot, O; Nabauer, M; Etsadashvili, K; Simantirakis, E; Haim, M; Azhari, A; Najafian, J; Santini, M; Mirrakhimov, E; Kulzida, K; Erglis, A; Poposka, L; Burg, M; Crijns, H; Erküner, Ö; Atar, D; Lenarczyk, R; Oliveira, M; Shah, D; Serdechnaya, E; Dan, G; Potpara, T; Diker, E; Lip, G; Lane, DBackground: Implementation of the Atrial fibrillation Better Care (ABC) pathway is recommended by guidelines on atrial fibrillation (AF), but the impact of adherence to ABC pathway in patients with cancer is unknown. Objectives: To investigate the adherence to ABC pathway and its impact on adverse outcomes in AF patients with cancer. Methods: Patients enrolled in the EORP-AF General Long-Term Registry were analyzed according to (i) No Cancer; and (ii) Prior or active cancer and stratified in relation to adherence to the ABC pathway. The composite Net Clinical Outcome (NCO) of all-cause death, major adverse cardiovascular events and major bleeding was the primary endpoint. Results: Among 6550 patients (median age 69 years, females 40.1%), 6005 (91.7%) had no cancer, while 545 (8.3%) had a diagnosis of active or prior cancer at baseline, with the proportions of full adherence to ABC pathway of 30.6% and 25.7%, respectively. Adherence to the ABC pathway was associated with a significantly lower occurrence of the primary outcome vs. non-adherence, both in 'no cancer' and 'cancer' patients [adjusted Hazard Ratio (aHR) 0.78, 95% confidence interval (CI): 0.66-0.92 and aHR 0.59, 95% CI 0.37-0.96, respectively]. Adherence to a higher number of ABC criteria was associated with a lower risk of the primary outcome, being lowest when 3 ABC criteria were fulfilled (no cancer: aHR 0.54, 95%CI: 0.36-0.81; with cancer: aHR 0.32, 95% CI 0.13-0.78). Conclusion: In AF patients with cancer enrolled in the EORP-AF General Long-Term Registry, adherence to ABC pathway was sub-optimal. Full adherence to ABC-pathway was associated with a lower risk of adverse events.
- Lifestyle and Impact on Cardiovascular Risk Factor Control in Coronary Patients Across 27 Countries: Results From the European Society of Cardiology ESC-EORP EUROASPIRE V RegistryPublication . Kotseva, K; De Backer, G; De Bacquer, D; Rydén, L; Hoes, A; Grobbee, D; Maggioni, A; Marques-Vidal, P; Jennings, C; Abreu, A; Aguiar, C; Badariene, J; Bruthans, J; Castro Conde, A; Cifkova, R; Crowley, J; Davletov, K; Deckers, J; De Smedt, D; De Sutter, J; Dilic, M; Dolzhenko, M; Dzerve, V; Erglis, A; Fras, Z; Gaita, D; Gotcheva, N; Heuschmann, P; Hasan-Ali, H; Jankowski, P; Lalic, N; Lehto, S; Lovic, D; Mancas, S; Mellbin, L; Milicic, D; Mirrakhimov, E; Oganov, R; Pogosova, N; Reiner, Z; Stöerk, S; Tokgözoğlu, L; Tsioufis, C; Vulic, D; Wood, DAims: The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design: A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods: Patients (<80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results: A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active <30 min 5 times/week. Forty-two per cent had a blood pressure ≥140/90 mmHg (≥140/85 if diabetic), 71% had low-density lipoprotein cholesterol ≥1.8 mmol/L (≥70 mg/dL) and 29% reported having diabetes. Cardioprotective medication was: anti-platelets 93%, beta-blockers 81%, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers 75% and statins 80%. Conclusion: A large majority of coronary patients have unhealthy lifestyles in terms of smoking, diet and sedentary behaviour, which adversely impacts major cardiovascular risk factors. A majority did not achieve their blood pressure, low-density lipoprotein cholesterol and glucose targets. Cardiovascular prevention requires modern preventive cardiology programmes delivered by interdisciplinary teams of healthcare professionals addressing all aspects of lifestyle and risk factor management, in order to reduce the risk of recurrent cardiovascular events.
- Percutaneous Ventricular Restoration (PVR) Therapy Using the Parachute Device in 100 Subjects with Ischaemic Dilated Heart Failure: One-Year Primary Endpoint Results of PARACHUTE III, a European TrialPublication . Thomas, M; Nienaber, C; Ince, H; Erglis, A; Vukcevic, V; Schäfer, U; Cruz Ferreira, R; Hardt, S; Verheye, S; Gama Ribeiro, V; Sugeng, L; Tamburino, CAIMS: This prospective, non-randomised, observational study conducted in Europe was designed in order to assess the long-term safety and efficacy of the Parachute device in ischaemic heart failure subjects as a result of left ventricle remodelling after anterior wall myocardial infarction. METHODS AND RESULTS: One hundred subjects with New York Heart Association Class II-IV ischaemic heart failure (HF), ejection fraction (EF) between 15% and 40%, and dilated akinetic or dyskinetic anterior-apical wall without the need to be revascularised were enrolled. The primary safety endpoint was procedural- or device-related major adverse cardiac cerebral events (MACCE). The secondary safety endpoint was the composite of mortality and morbidity. Secondary efficacy endpoints included haemodynamic measurements determined by echocardiography, LV volume indices, and assessment of functional improvement measured by a standardised six-minute walk test. Of the 100 subjects enrolled, device implantation was successful in 97 (97%) subjects. The one-year rates of the primary and secondary safety endpoints were 7% and 32.3%, respectively. The secondary endpoints, LV volume reduction (p<0.0001) and six-minute walk distance improvement (p<0.01), were achieved. CONCLUSIONS: The favourable outcomes observed in this high-risk population provide reassuring safety and efficacy data to support adoption of this technology as a therapeutic option for HF subjects.